Renin-angiotensin system blocking drugs

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 19, Issue 1, 2014, Pages 14-33

  Robles, Nicolás Roberto ^a,b   Cerezo, Isis ^b   Hernandez Gallego, Roman ^b  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b HOSPITAL INFANTA CRISTINA   (Spain)

Author keywords

hypertension; renin angiotensin system

Indexed keywords

ALISKIREN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; CANDESARTAN; CAPTOPRIL; CILAZAPRIL; DELAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPROSARTAN; FOSINOPRIL; IMIDAPRIL; IRBESARTAN; LISINOPRIL; LOSARTAN; MOEXIPRIL; OLMESARTAN; PERINDOPRIL; QUINAPRIL; RAMIPRIL; RENIN INHIBITOR; TELMISARTAN; TRANDOLAPRIL; VALSARTAN;

ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE ACTIVITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; DEMENTIA; DIABETES MELLITUS; DIABETIC RETINOPATHY; DRUG EFFECT; DRUG MEGADOSE; DRUG SAFETY; DRUG USE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERTENSION; KIDNEY DISEASE; META ANALYSIS (TOPIC); NEOPLASM; PHARMACOGENETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTEMATIC REVIEW (TOPIC);

HYPERTENSION; RENIN-ANGIOTENSIN SYSTEM;

AMIDES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; FUMARATES; HUMANS; HYPERTENSION; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 84890928191     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248413501018     Document Type: Review

References (185)

1. Ruilope LM, Rosei EA, Bakris GL, et al. Angiotensin receptor blockers: therapeutic targets and cardiovascular protection. Blood Press. 2005 ; 14 ((4 )). 196-209
2. Werner C, Baumhakel M, Teo KK, et al. RAS blockade with ARB and ACEIs: current perspective on rationale and patient selection. Clin Res Cardiol. 2008 ; 97 ((7 )). 418-431
3. Unger T. Targeting cardiovascular protection: the concept of dual renin-angiotensin system control. Medscape J Med. 2008 ; 10 (suppl). S4
4. Steckelings UM, Kaschina E, Unger T. The AT2 receptor - a matter of love and hate. Peptides. 2005 ; 26 (8). 1401-1409
5. Cesari M, Rossi GP, Pessina AC. Biological properties of the angiotensin peptides other than angiotensin II: implications for hypertension and cardiovascular diseases. J Hypertens. 2002 ; 20 (5). 793-799
6. Dan Janser AH, Batenburg W, van Esch JH. Prorenin and the (pro)renin receptor - an update. Nephrol Dial Transplant. 2007 ; 22 (5). 1288-1292
7. Kaschina E, Grzesiak A, Li J, et al. Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction?. Circulation. 2008 ; 118 ((24 )). 2523-2532
8. Jadhav M, Yeola C, Zope G, Nabar A. Aliskiren, the first direct renin inhibitor for treatment of hypertension: the path of its development. J Postgrad Med. 2012 ; 58 (1). 32-38
9. Fleming I, Kohlstedt K, Busse R. New fACEs to the renin-angiotensin system. Physiology (Bethesda). 2005 ; 20: 91-95
10. MacFadyen RJ, Lee AF, Morton JJ, Pringle SD, Struthers AD. How often are angiotensin II and aldosterone concentrations raised during chronic ACEI treatment in cardiac failure?. Heart. 1999 ; 82 ((1 )). 57-61
11. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive HF and their relation to mortality. CONSENSUS Trial Study Group. Circulation. 1990 ; 82 ((5 )). 1730-1736
12. Dicpinigaitis PV. ACEI-induced cough: ACCP evidence-based clinical practice guidelines. Chest. 2006 ; 129 ((1 )). 169S - 173S
13. Sondhi D, Lippmann M, Murali G. Airway compromise due to ACEI-induced angioedema: clinical experience at a large community teaching hospital. Chest. 2004 ; 126 ((2 )). 400-404
14. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000 ; 342 ((3 )). 145-153
15. FDA. http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/ 020312s033lbl.pdf. Accessed April 25, 2013.
16. Greathouse MK, Weir MR. The role of ARBs alone or with HCTZ in the treatment of hypertension and prevention of cardiovascular and renal complications. Postgrad Med. 2012 ; 124 (2). 40-52
17. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003 ; 362 ((9395 )). 1527-1535
18. FDA. http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/ 200796s002lbl.pdf. Accessed April 25, 2013.
19. Oliver JA. Receptor-mediated actions of renin and prorenin. Kidney Int. 2006 ; 69 ((1 )). 13-15
20. Nguyen G, Burckle C, Sraer JD. The renin receptor: the facts, the promise and the hope. Curr Opin Nephrol Hypertens. 2003 ; 12 ((1 )). 51-55
21. Staessen JA, Li Y, Richart T. Oral renin inhibitors. Lancet. 2006 ; 368 (9545). 1449-1456
22. Ferro A, Gilbert R, Krum H. Importance of renin in BP regulation and therapeutic potential of renin inhibition. Int J Clin Pract. 2006 ; 60 ((5 )). 577-581
23. de Galan BE, Perkovic V, Ninomiya T, et al. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol. 2009 ; 20 (4). 883-892
24. Heerspink HJ, Ninomiya T, Perkovic V, et al. Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. Eur Heart J. 2010 ; 31 (23). 2888-2896
25. van Vark LC, Bertrand M, Akkerhuis KM, et al. ACEIs reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J. 2012 ; 33 (16). 2088-2097
26. Baker WL, Coleman CI, Kluger J, et al. Systematic review: comparative effectiveness of ACEIs or angiotensin II-receptor blockers for ischemic heart disease. Ann Intern Med. 2009 ; 151 (12). 861-871
27. Fretheim A, Odgaard-Jensen J, Brørs O, et al. Comparative effectiveness of antihypertensive medication for primary prevention of cardiovascular disease: systematic review and multiple treatments meta-analysis. BMC Med. 2012 ; 10: 33
28. Volpe M, Tocci G, Sciarretta S, Verdecchia P, Trimarco B, Mancia G. Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials. J Hypertens. 2009 ; 27 (5). 941-946
29. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009 ; 338: b1665
30. Reboldi G, Angeli F, Cavallini C, Gentile G, Mancia G, Verdecchia P. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. J Hypertens. 2008 ; 26 ((7 )). 1282-1289
31. Savarese G, Costanzo P, Cleland JG, et al. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure. J Am Coll Cardiol. 2013 ; 61 ((2 )). 131-142
32. Nakao YM, Teramukai S, Tanaka S, et al. Effects of renin-angiotensin system blockades on cardiovascular outcomes in patients with diabetes mellitus: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2012 ; 96 ((1 )). 68-75
33. McAlister FA. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are beneficial in normotensive atherosclerotic patients: a collaborative meta-analysis of randomized trials. Eur Heart J. 2012 ; 33 (4). 505-514
34. Shibata MC, Tsuyuki RT, Wiebe N. The effects of angiotensin-receptor blockers on mortality and morbidity in heart failure: a systematic review. Int J Clin Pract. 2008 ; 62 ((9 )). 1397-1402
35. Staessen JA, Richart T, Wang Z, Thijs L. Implications of recently published trials of blood pressure-lowering drugs in hypertensive or high-risk patients. Hypertension. 2010 ; 55 (4). 819-831
36. Mujib M, Patel K, Fonarow GC, et al. Angiotensin-converting enzyme inhibitors and outcomes in heart failure and preserved ejection fraction. Am J Med. 2013 ; 126 (5). 401-410
37. Sharma P, Blackburn RC, Parke CL, McCullough K, Marks A, Black C. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease. Cochrane Database Syst Rev. 2011 ; ((10 )). CD007751
38. Geng DF, Jin DM, Wu W, Liang YD, Wang JF. Angiotensin converting enzyme inhibitors for prevention of new-onset type 2 diabetes mellitus: a meta-analysis of 72,128 patients [published online July 16, 2012]. Int J Cardiol. 2012 ;:
39. Sipahi I, Chou J, Mishra P, Debanne SM, Simon DI, Fang JC. Meta-analysis of randomized controlled trials on effect of ACEIs on cancer risk. Am J Cardiol. 2011 ; 108 ((2 )). 294-301
40. Makani H, Messerli FH, Romero J, et al. Meta-analysis of randomized trials of angioedema as an adverse event of RAS inhibitors. Am J Cardiol. 2012 ; 110 ((3 )). 383-391
41. Li YF, Zhu XM, Liu F, et al. Angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism and ACEI-related cough: a meta-analysis. PLoS One. 2012 ; 7 ((6 )). e37396
42. Li DK, Yang C, Andrade S, Tavares V, Ferber JR. Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: a retrospective cohort study. BMJ. 2011 ; 343: d5931
43. De Denus S. Pharmacogenomic testing for ACEIs: getting ready for prime time. Pharmacogenomics. 2010 ; 11 ((10 )). 1345-1348
44. Schelleman H, Klungel OH, Witteman JC, et al. Interaction between polymorphisms in the renin-angiotensin-system and ACEI or beta-blocker use and the risk of myocardial infarction and stroke. Pharmacogenomics J. 2008 ; 8 ((6 )). 400-407
45. Nordestgaard BG, Kontula K, Benn M, et al. Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the life study. Pharmacogenet Genomics. 2010 ; 20 ((2 )). 77-85
46. Brugts JJ, de Maat MP, Danser AH, Boersma E, Simoons ML. Individualised therapy of angiotensin converting enzyme (ACE) inhibitors in stable coronary artery disease: overview of the primary results of the PERindopril GENEtic association (PERGENE) study. Neth Heart J. 2012 ; 20 (1). 24-32
47. Srivastava K, Chandra S, Bhatia J, Narang R, Saluja D. Association of angiotensinogen (M235T) gene polymorphism with BP lowering response to angiotensin converting enzyme inhibitor (Enalapril). J Pharm Pharmaceut Sci. 2012 ; 15 ((3 )). 399-406
48. Maitland-van der Zee AH, van Wieren-de Wijer DB, de Boer A, et al. Genetic variation in the renin-angiotensin system, use of renin-angiotensin system inhibitors and the risk of myocardial infarction. J Renin Angiotensin Aldosterone Syst. 2011 ; 12 ((3 )). 208-214
49. Mann JF, Schmieder RE, McQueen M, et al. The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET®) Investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET® study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008 ; 372 ((9638 )). 547-553
50. Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to ACEIs: a randomized controlled trial. Lancet. 2008 ; 372 (9944). 1174-1183
51. Verdecchia P, Sleight P, Mancia G, et al. Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease. Circulation. 2009 ; 120 (14). 1380-1389
52. FDA. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/ 020850s033lbl.pdf. Accessed April 25, 2013.
53. EMEA. Committee for medicinal products for human use post-authorisation summary of positive opinion for Micardis (telmisartan). EMEA/CHMP/676934/2009. www.ema.europa.eu/pdfs/human/opinion/Micardis-67693409en.pdf. Accessed January 30, 2010.
54. Kasanuki H, Hagiwara N, Hosoda S, et al. Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). Eur Heart J. 2009 ; 30 (10). 1203-1212
55. Ogihara T, Ueshima K, Nakao K, et al. Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex). Hypertens Res. 2011 ; 34 ((12 )). 1295-1301
56. Kronish IM, Woodward M, Sergie Z, Ogedegbe G, Falzon L, Mann DM. Meta-analysis: impact of drug class on adherence to antihypertensives. Circulation. 2011 ; 123 (15). 1611-1621
57. Heran BS, Wong MM, Heran IK, Wright JM. Blood pressure lowering efficacy of ARBs for primary hypertension. Cochrane Database Syst Rev. 2008 ; ((4 )). CD003822
58. Bramslage P, Hasford J. Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment - a review. Cardiovasc Diabetol. 2009 ; 8: 18
59. Hazan L, Hernández Rodriguez OA, Bhorat AE, Miyazaki K, Tao B, Heyrman R. A double-blind, dose-response study of the efficacy and safety of olmesartan medoxomil in children and adolescents with hypertension. Hypertension. 2010 ; 55 (6). 1323-1330
60. Chaturvedi N, Porta M, Klein R, et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet. 2008 ; 372 (9647). 1394-1402
61. Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med. 2009 ; 361 (1). 40-51
62. Sjølie AK, Klein R, Porta M, et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomized placebo-controlled trial. Lancet. 2008 ; 372 (9647). 1385-1393
63. Verdecchia P, Angeli F, Cavallini C, et al. Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis. Eur Heart J. 2009 ; 30 (6). 679-688
64. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail. 2008 ; 10 ((10 )). 933-989
65. Shibata MC, Tsuyuki RT, Wiebe N. The effects of angiotensin-receptor blockers on mortality and morbidity in heart failure: a systematic review. Int J Clin Pract. 2008 ; 62 ((9 )). 1397-1402
66. Heran BS, Musini VM, Bassett K, Taylor RS, Wright JM. ARBs for heart failure. Cochrane Database Syst Rev. 2012 ; 4: CD003040
67. Meune C, Wahbi K, Duboc D, Weber S. Meta-analysis of renin-angiotensin- aldosterone blockade for heart failure in presence of preserved left ventricular function. J Cardiovasc Pharmacol Ther. 2011 ; 16 ((3-4 )). 368-735
68. Rajagopalan S, Arora A, Shafiq N, et al. Pharmacotherapy of heart failure with normal ejection fraction (HFNEF) - a systematic review. Br J Clin Pharmacol. 2011 ; 72 (3). 369-380
69. Shah RV, Desai AS, Givertz MM. The effect of renin-angiotensin system inhibitors on mortality and heart failure hospitalization in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis. J Card Fail. 2010 ; 16 ((3 )). 260-267
70. Lund LH, Benson L, Dahlstrom U, Edner M. Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction. JAMA. 2012 ; 308 ((20 )). 2108-2117
71. Zhou MS, Schulman IH. Prevention of diabetes in hypertensive patients: results and implications from the VALUE trial. Vasc Health Risk Manag. 2009 ; 5 (1). 361-368
72. Tocci G, Paneni F, Palano F, et al. Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and diabetes: a meta-analysis of placebo-controlled clinical trials. Am J Hypertens. 2011 ; 24 ((5 )). 582-590
73. Al-Mallah M, Khawaja O, Sinno M, Alzohaili O, Samra AB. Do angiotensin converting enzyme inhibitors or angiotensin receptor blockers prevent diabetes mellitus? A meta-analysis. Cardiol J. 2010 ; 17 ((5 )). 448-456
74. Geng DF, Jin DM, Wu W, Xu Y, Wang JF. ARBs for prevention of new-onset type 2 diabetes: a meta-analysis of 59,862 patients. Int J Cardiol. 2012 ; 155 ((2 )). 236-242
75. Grimm C, Köberlein J, Wiosna W, Kresimon J, Kiencke P, Rychlik R. New-onset diabetes and antihypertensive treatment. GMS Health Technol Assess. 2010 ; 6 :
76. Coleman CI, Baker WL, Kluger J, White CM. Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials. J Hypertens. 2008 ; 26 ((4 )). 622-629
77. Sipahi I, Debanne SM, Rowland DY, Simon DI, Fung JC. Angiotensin receptor blockade and risk of cancer: meta-analysis of randomized controlled trials. Lancet Oncol. 2010 ; 11 ((7 )). 627-636
78. Julius S, Kjeldsen SE, Weber MA. Angiotensin-receptor blockade, cancer, and concerns. Lancet Oncol. 2010 ; 11 ((9 )). 820-821
79. Bangalore S, Kumar S, Kjeldsen SE, et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol. 2011 ; 12 (1). 65-82
80. Yoon C, Yang HS, Jeon I, Chang Y, Park SM. Use of angiotensin-converting- enzyme inhibitors or angiotensin-receptor blockers and cancer risk: a meta-analysis of observational studies. CMAJ. 2011 ; 183 (14). E1073 - E1084
81. Coleman CI, Baker WL, Kluger J, White CM. Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials. J Hypertens. 2008 ; 26 ((4 )). 622-629
82. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. J Hypertens. 2011 ; 29 (4). 623-635
83. Azoulay L, Assimes TL, Yin H, Bartels DB, Schiffrin EL, Suissa S. Long-term use of angiotensin receptor blockers and the risk of cancer. PLoS One. 2012 ; 7 (12). e50893
84. Pasternak B, Svanström H, Callréus T, Melbye M, Hviid A. Use of angiotensin receptor blockers and the risk of cancer. Circulation. 2011 ; 123 ((16 )). 1729-1736
85. Hallas J, Christensen R, Andersen M, Friis S, Bjerrum L. Long term use of drugs affecting the RAS and the risk of cancer: a population-based case-control study. Br J Clin Pharmacol. 2012 ; 74 ((1 )). 180-188
86. Bhaskaran K, Douglas I, Evans S, van Staa T, Smeeth L. ARBs and risk of cancer: cohort study among people receiving antihypertensive drugs in UK General Practice Research Database. BMJ. 2012 ; 344: e2697
87. Wang KL, Liu CJ, Chao TF, Huang CM, Wu CH, Chen TJ, Chiang CE. Long-term use of angiotensin II receptor blockers and risk of cancer: A population-based cohort analysis. Int J Cardiol. 2012 Jun 16 ;:
88. Mc Menamin UC, Murray LJ, Cantwell MM, Hughes CM. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: a systematic review. Cancer Causes Control. 2012 ; 23 ((2 )). 221-230
89. Daien V, Duny Y, Ribstein J, et al. Treatment of hypertension with RAS inhibitors and renal dysfunction: a systematic review and meta-analysis. Am J Hypertens. 2012 ; 25 ((1 )). 126-132
90. Robles NR, Hernandez-Gallego R. Blood pressure in renal disease: how accomplish the goal?. Cardiovasc Ther. 2012 ; 30 (4). 193-198
91. Levey AS, Cattran D, Friedman A, et al. Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis. 2009 ; 54 (2). 205-226
92. Glassock RJ. Is the presence of microalbuminuria a relevant marker of kidney disease?. Curr Hypertens Rep. 2010 ; 12 ((5 )). 364-368
93. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomized, double-blind, controlled trial. Lancet. 2008 ; 372 (9638). 547-553
94. Mann JF, Schmieder RE, Dyal L, et al. Effect of telmisartan on renal outcomes: a randomized trial. Ann Intern Med. 2009 ; 151 (1). 1-10
95. Tobe SW, Clase CM, Gao P, et al. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND Studies. Circulation. 2011 ; 123 (10). 1098-1107
96. Geng DF, Sun WF, Yang L, En G, Wang JF. Antiproteinuric effect of ARBs in normotensive patients with proteinuria: a meta-analysis of randomized controlled trials [published online February 1, 2013]. J Renin Angiotensin Aldosterone Syst. 2013 ;:
97. Haller H, Ito S, Izzo JL, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011 ; 364 (10). 907-917
98. Menne J, Izzo JL, Ito S, et al. Prevention of microalbuminuria in patients with type 2 diabetes and hypertension. J Hypertens. 2012 ; 30 (4). 811-818
99. Sarafidis PA, Stafylas PC, Kanaki AI, Lasaridis AN. Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis. Am J Hypertens. 2008 ; 21 ((8 )). 922-929
100. Vejakama P, Thakkinstian A, Lertrattananon D, Ingsathit A, Ngarmukos C, Attia J. Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis. Diabetologia. 2012 ; 55 (3). 566-578
101. De Leeuw PW, Ruilope LM, Palmer CR, et al. Clinical significance of renal function in hypertensive patients at high risk: results from the INSIGHT trial. Arch Intern Med. 2004 ; 164 ((22 )). 2459-2464
102. Saruta T, Hayashi K, Ogihara T, Nakao K, Fukui T, Fukiyama K. Effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease: subanalysis of the CASE-J Study. Hypertens Res. 2009 ; 32 ((6 )). 505-512
103. Maione A, Navaneethan SD, Graziano G, Mitchell R, Johnson D, Mann JF, et al. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials. Nephrol Dial Transplant. 2011 ; 26 (9). 2827-2847
104. Balamuthusamy S, Srinivasan L, Verma M, et al. Renin-angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis. Am Heart J. 2008 ; 155 ((5 )). 791-805
105. Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol. 2005 ; 45 ((1 )). 1832-1839
106. Schneider MP, Hua TA, Bohm M, Wachtell K, Kjeldsen SE, Schmieder RE. Prevention of atrial fibrillation by renin-angiotensin system inhibition a meta-analysis. J Am Coll Cardiol. 2010 ; 55 ((21 )). 2299-2307
107. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010 ; 31 ((19 )). 2369-2429
108. Disertori M, Latini R, Barlera S, et al. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med. 2009 ; 360 ((16 )). 1606-1617
109. Goette A, Schön N, Kirchhof P, et al. Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial. Circ Arrhythm Electrophysiol. 2012 ; 5 ((1 )). 43-51
110. Schneider MP, Hua TA, Böhm M, Wachtell K, Kjeldsen SE, Schmieder RE. Prevention of atrial fibrillation by renin-angiotensin system inhibition a meta-analysis. J Am Coll Cardiol. 2010 ; 55 (21). 2299-2307
111. Bhuriya R, Singh M, Sethi A, et al. Prevention of recurrent atrial fibrillation with ACEIs or ARBs: a systematic review and meta-analysis of randomized trials. J Cardiovasc Pharmacol Ther. 2011 ; 16 ((2 )). 178-184
112. Disertori M, Barlera S, Staszewsky L, Latini R, Quintarelli S, Franzosi MG. Systematic review and meta-analysis: renin-angiotensin system inhibitors in the prevention of atrial fibrillation recurrences: an unfulfilled hope. Cardiovasc Drugs Ther. 2012 ; 26 (1). 47-54
113. Webb AJ, Rothwell PM. Blood pressure variability and risk of new-onset atrial fibrillation: a systematic review of randomized trials of antihypertensive drugs. Stroke. 2010 ; 41 (9). 2091-2093
114. Schaer BA, Schneider C, Jick SS, Conen D, Osswald S, Meier CR. Risk for incident atrial fibrillation in patients who receive antihypertensive drugs: a nested case-control study. Ann Intern Med. 2010 ; 152 (2). 78-84
115. Weir MR, Hollenberg NK, Zappe DH, et al. Antihypertensive effects of double the maximum dose of valsartan in African-American patients with type 2 diabetes mellitus and albuminuria. J Hypertens. 2010 ; 28 (1). 186-193
116. Lee YJ, Jang HR, Kim SG, et al. Renoprotective efficacy of valsartan in chronic non-diabetic proteinuric nephropathies with RAS gene polymorphisms. Nephrology (Carlton). 2011 ; 16 ((5 )). 502-510
117. Khatib R, Joseph P, Briel M, Yusuf S, Healey J. Blockade of the renin-angiotensin-aldosterone system (RAAS) for primary prevention of non-valvular atrial fibrillation: a systematic review and meta analysis of randomized controlled trials [published online March 13, 2013]. Int J Cardiol. 2012 ;:
118. Huang G, Xu JB, Liu JX, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers decrease the incidence of atrial fibrillation: a meta-analysis. Eur J Clin Invest. 2011 ; 41 (7). 719-733
119. Parving HH, de Zeeuw D, Cooper ME, et al. ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy. J Am Soc Nephrol. 2008 ; 19: 771-779
120. Liu H, Zhang S, Jiang S, et al. Renin-angiotensin-aldosterone system gene polymorphisms and antihypertensive response to irbesartan in Chinese hypertensives. Methods Find Exp Clin Pharmacol. 2008 ; 30 ((4 )). 307-312
121. Turner ST, Bailey KR, Schwartz GL, Chapman AB, Chai HS, Boerwinkle E. Genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker. Hypertension. 2012 ; 59 ((6 )). 1204-1211
122. Dahlof B, Devereux R, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002 ; 359 (9311). 995
123. Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet. 2004 ; 363 (9426). 2049-2051
124. Schrader J, Lüders S, Kulschewski A, et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke. 2005 ; 36 ((6 )). 1218-1226
125. Larsen K, Hornnes N, Boysen G. Does the MOSES study provide sufficient evidence for eprosartan against nitrendipine?. Stroke. 2006 ; 37 (6). 1357
126. Lu GC, Cheng JW, Zhu KM, Ma XJ, Shen FM, Su DF. A systematic review of angiotensin receptor blockers in preventing stroke. Stroke. 2009 ; 40 (12). 3876-3878
127. Schrader J, Lüders S, Kulschewski A, et al. The ACCESS study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke. 2003 ; 34 ((7 )). 1699-1703
128. Fournier A, Messerli FH, Achard JM, Fernandez L. Cerebroprotection mediated by angiotensin II: a hypothesis supported by recent randomized clinical trials. J Am Coll Cardiol. 2004 ; 43 (8). 1343-1347
129. Sandset EC, Bath PM, Boysen G, et al. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. Lancet. 2011 ; 377 (9767). 741-750
130. Bath PM, Martin RH, Palesch Y, et al. Effect of telmisartan on functional outcome, recurrence, and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. Stroke. 2009 ; 40 (11). 3541-3546
131. Weber R, Weimar C, Blatchford J, et al. Telmisartan on top of antihypertensive treatment does not prevent progression of cerebral white matter lesions in the prevention regimen for effectively avoiding second strokes (PRoFESS) MRI substudy. Stroke. 2012 ; 43 ((9 )). 2336-2342
132. Anderson C, Teo K, Gao P, et al. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurol. 2011 ; 10 (1). 43-53
133. Sacco RL, Diener HC, Yusuf S, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008 ; 359 (12). 1238-1251
134. Hanon O, Berrou JP, Negré-Pages L, et al. Effects of hypertension therapy based on eprosartan on systolic arterial blood pressure and cognitive function: primary results of the Observational Study on Cognitive function and Systolic Blood Pressure Reduction open-label study. J Hypertens. 2008 ; 26 (8). 1642-1650
135. Petrella RJ, Shlyakhto E, Konradi AO, Berrou JP, Sedefdjian A, Pathak A. Blood pressure responses to hypertension treatment and trends in cognitive function in patients with initially difficult-to-treat hypertension: a retrospective subgroup analysis of the Observational Study on Cognitive Function and SBP Reduction (OSCAR) study. J Clin Hypertens (Greenwich). 2012 ; 14 ((2 )). 78-84
136. Li NC, Lee A, Whitmer RA, et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ. 2010 ; 340: b5465
137. Hsu CY, Huang CC, Chan WL, et al. Angiotensin-receptor blockers and risk of Alzheimer's disease in hypertension population - a nationwide cohort study. Circ J. 2013 ; 77 ((2 )). 405-410
138. Johnson ML, Parikh N, Kunik ME, et al. Antihypertensive drug use and the risk of dementia in patients with diabetes mellitus. Alzheimers Dement. 2012 ; 8 ((5 )). 437-444
139. Makani H, Messerli FH, Romero J, et al. Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors. Am J Cardiol. 2012 ; 110 ((3 )). 383-391
140. Toh S, Reichman ME, Houstoun M, et al. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system [published online October 15, 2012]. Arch Intern Med. 2012 ;:
141. Caldeira D, David C, Sampaio C. Tolerability of angiotensin-receptor blockers in patients with intolerance to angiotensin-converting enzyme inhibitors: a systematic review and meta-analysis. Am J Cardiovasc Drugs. 2012 ; 12 ((4 )). 263-277
142. Haymore BR, Yoon J, Mikita CP, Klote MM, DeZee KJ. Risk of angioedema with angiotensin receptor blockers in patients with prior angioedema associated with angiotensin-converting enzyme inhibitors: a meta-analysis. Ann Allergy Asthma Immunol. 2008 ; 101 ((5 )). 495-499
143. Bullo M, Tschumi S, Bucher BS, Bianchetti MG, Simonetti GD. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review. Hypertension. 2012 ; 60 ((2 )). 444-450
144. Moretti ME, Caprara D, Drehuta I, et al. The fetal safety of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers [published online December 13, 2011]. Obstet Gynecol Int. 2012 ; 658310: 2012
145. Düssing R. Angiotensin II receptor blockers dosage: how high should we go?. Int J Clin Pract. 2006 ; 60 ((2 )). 179-183
146. Blacklock CL, Hirst JA, Taylor KS, Stevens RJ, Roberts NW, Farmer AJ. Evidence for a dose effect of RAS inhibition on progression of microalbuminuria in type 2 diabetes: a meta-analysis. Diabet Med. 2011 ; 28 ((10 )). 1182-1187
147. Konstam MA, Neaton JD, Dickstein K, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet. 2009 ; 374 ((9704 )). 1840-1848
148. Blacklock CL, Hirst JA, Taylor KS, Stevens RJ, Roberts NW, Farmer AJ. Evidence for a dose effect of renin-angiotensin system inhibition on progression of microalbuminuria in type 2 diabetes: a meta-analysis. Diabet Med. 2011 ; 28 ((10 )). 1182-1187
149. MacKinnon M, Shurraw S, Akbari A, Knoll GA, Jaffey J, Clark HD. Combination therapy with an angiotensin receptor blocker and an ACEI in proteinuric renal disease: a systematic review of the efficacy and safety data. Am J Kidney Dis. 2006 ; 48 (1). 8-20
150. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press. 2009 ; 18 (6). 308-347
151. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003 ; 349: 1893-1906
152. Russo D, Minutolo R, Pisani A, et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nefropathy. Am J Kidney Dis. 2001 ; 38 (1). 18-25
153. Ruilope LM, Aldigier JC, Ponticelli C, Oddou-Stock P, Botteri F, Mann JF. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease. J Hypertens. 2000 ; 18 (1). 89-95
154. Luño J, Barrio V, Goicoechea MA, et al. Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies. Kidney Int. 2002 ; 62 (suppl 82). S47 - S52
155. Robles NR, Ruiz Jiménez B, Hernandez Gallego R, et al. Dual renin-angiotensin system blockade in patients with single functioning kidney and proteinuria. Eur J Intern Med. 2009 ; 20 (2). 186-189
156. Robles NR, Fernandez-Carbonero E, Romero B, Sanchez Casado E, Cubero JJ. Long-term antiproteinuric effect of dual renin-angiotensin system blockade. Cardiovasc Ther. 2009 ; 27 (2). 101-107
157. Jacobsen P, Andersen S, Rossing K, Hansen BV, Parving HH. Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy. Nephrol Dial Transplant. 2002 ; 17 (6). 1019-1024
158. Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000 ; 321 (7274). 1440-1444
159. Kunz R, Friedrich C, Wolbers M, Mann JFE. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease. Ann Intern Med. 2008 ; 148 ((1 )). 30-48
160. Catapano F, Chiodini P, De Nicola L, et al. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression. Am J Kidney Dis. 2008 ; 52 ((3 )). 475-485
161. Imai E, Chan JC, Ito S, et al. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia. 2011 ; 54 (12). 2978-2986
162. Fernandez Juarez G, Luño J, Barrio V, et al. Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial. Am J Kidney Dis. 2012 ;:
163. Lakhdar R, Al-Mallah MH, Lanfear DE. Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials. J Card Fail. 2008 ; 14 ((3 )). 181-188
164. Robles NR, Cancho B, Barroso S, Martin MV, Sanchez Casado E. Untoward effects of dual rennin-angiotensin system blockade: influence of previous chronic renal failure. Intl J Clin Pract. 2006 ; 60 (9). 1035-1039
165. Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure. Circulation. 2009 ; 20 (16). 1577-1584
166. McAlister FA, Zhang J, Tonelli M, Klarenbach S, Manns BJ, Hemmelgarn BR. The safety of combining angiotensin-converting-enzyme inhibitors with angiotensin-receptor blockers in elderly patients: a population-based longitudinal analysis. CMAJ. 2011 ; 183 (6). 655-662
167. McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RSOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation. 1999 ; 100 ((10 )). 1056-1064
168. McMurray JJV, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting enzyme inhibitors: the CHARM-Added trial. Lancet. 2003 ; 362 ((9386 )). 767-771
169. Makani H, Bangalore S, Desouza KA, Shah A, Messerli FH. Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomized trials. BMJ. 2013 ; 346: f360
170. Kuenzli A, Bucher HC, Anand I, et al. Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACEIs alone in patients with heart failure. PLoS One. 2010 ; 5 (4). e9946
171. Harel Z, Gilbert C, Wald R, et al. The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis. BMJ. 2012 ; 344: e42
172. White WB, Bresalier R, Kaplan AP, et al. Safety and tolerability of the direct renin inhibitor aliskiren in combination with angiotensin receptor blockers and thiazide diuretics: a pooled analysis of clinical experience of 12,942 patients. J Clin Hypertens (Greenwich). 2011 ; 13 (7). 506-516
173. White WB, Bresalier R, Kaplan AP, et al. Safety and tolerability of the direct renin inhibitor aliskiren: a pooled analysis of clinical experience in more than 12,000 patients with hypertension. J Clin Hypertens (Greenwich). 2010 ; 12 (10). 765-775
174. Chang J, Yang W, Kahler KH, et al. Compliance, persistence, healthcare resource use, and treatment costs associated with aliskiren plus ARB versus ACE inhibitor plus ARB combination therapy: in US patients with hypertension. Am J Cardiovasc Drugs. 2011 ; 11 ((1 )). 21-32
175. ASPIRE HIGHER clinical program expands to 35,000 patients in 14 trials, the largest cardio-renal outcomes program ever. http://www.novartis.be/ downloads/nl/pers-media/berichten/reports/2008-0717financial-report-s1-2008-en. pdf. Accessed June 25, 2010.
176. McMurray J, Pitt B, Latini R, et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail. 2008 ; 1 (1). 17-24
177. Scirica BM, Morrow DA, Bode C, et al. Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 Trial. Eur Heart J. 2010 ; 31 (16). 1993-2005
178. Solomon SD, Appelbaum E, Manning WJ, et al. Aliskiren in Left Ventricular Hypertrophy (ALLAY) Trial Investigators. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation. 2009 ; 119 (4). 530-537
179. Solomon SD. Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with left ventricular dysfunction: ASPIRE. Presented at: American College of Cardiology 59th Annual Scientific Sessions; March 13-16, 2010; Atlanta, GA.
180. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollengerg NH. Aliskiren combined with losartan in Type 2 diabetes and nephropathy. N Engl J Med. 2008 ; 358 (23). 2433-2446
181. Parving HH, Brenner BM, McMurray JJ, et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant. 2009 ; 24 (5). 1663-1671
182. http://www.novartis.com/newsroom/media-releases/en/2011/1572562.shtml. Accessed December 24, 2011.
183. http://www.ema.europa.eu/docs/en-GB/document-library/Press-release/2011/ 12/WC500119982.pdf. Accessed March 15, 2013.
184. http://www.fda.gov/drugs/drugsafety/ucm300889.htm. Accessed March 15, 2013.
185. Mann JF, Anderson C, Gao P, et al. ONTARGET investigators. Dual inhibition of the renin-angiotensin system in high-risk diabetes and risk for stroke and other outcomes: results of the ONTARGET trial. J Hypertens. 2013 ; 31 ((2 )). 414-421